Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21703101 | 0.87 | MAP4K1 (0.41) | MAP4K1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25952784 | 0.78 | MAP4K1 (0.55) | MAP4K1 | |
| SCHEMBL21684242 | 0.76 | MAP4K1 (0.64) | MAP4K1 | |
| SCHEMBL21684239 | 0.76 | MAP4K1 (0.64) | MAP4K1 | |
| SCHEMBL21684246 | 0.76 | MAP4K1 (0.64) | MAP4K1 | |
| SCHEMBL23452919 | 0.75 | MAP4K1 (0.74) | MAP4K1 | |
| SCHEMBL25938804 | 0.73 | MAP4K1 (0.43) | MAP4K1 | |
| SCHEMBL23452918 | 0.73 | MAP4K1 (0.41) | MAP4K1PKM | |
| SCHEMBL25938742 | 0.73 | MAP4K1 (0.39) | MAP4K1 | |
| SCHEMBL21703430 | 0.72 | P2RX3 (0.33) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |